The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! About 374,866 shares traded hands or 84.64% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has declined 3.59% since April 20, 2016 and is downtrending. It has underperformed by 8.15% the S&P500.
The move comes after 6 months positive chart setup for the $609.43 million company. It was reported on Nov, 22 by Barchart.com. We have $32.90 PT which if reached, will make NASDAQ:ENTA worth $18.28 million more.
Analysts await Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report earnings on November, 28. They expect $-0.28 EPS, down 196.55% or $0.57 from last year’s $0.29 per share. After $-0.06 actual EPS reported by Enanta Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 366.67% negative EPS growth.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage
Out of 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. Enanta Pharmaceuticals Inc has been the topic of 11 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Friday, October 23 the stock rating was downgraded by Barclays Capital to “Underweight”. On Friday, October 23 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. Zacks downgraded the shares of ENTA in a report on Friday, August 7 to “Buy” rating. JP Morgan maintained Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Tuesday, August 9 with “Overweight” rating. JMP Securities downgraded the stock to “Market Perform” rating in Thursday, April 28 report. TheStreet downgraded the stock to “Buy” rating in Saturday, August 8 report.
According to Zacks Investment Research, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.53 in Q2 2016. Its up 0.83, from 0.7 in 2016Q1. The ratio is positive, as 29 funds sold all Enanta Pharmaceuticals Inc shares owned while 42 reduced positions. 9 funds bought stakes while 41 increased positions. They now own 13.13 million shares or 4.44% less from 13.75 million shares in 2016Q1.
Cornerstone Capital Management Hldgs Ltd Co last reported 0% of its portfolio in the stock. Tiaa Cref Invest Management Ltd Limited Liability Company holds 89,624 shares or 0% of its portfolio. Invesco Limited holds 0% or 61,041 shares in its portfolio. Glenmede Tru Na last reported 0% of its portfolio in the stock. Krensavage Asset Management Limited Com last reported 906,930 shares in the company. Us Comml Bank De reported 5,408 shares or 0% of all its holdings. Baker Bros Advsr Ltd Partnership holds 0.02% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 75,357 shares. Armistice Limited Co has 2.01% invested in the company for 240,000 shares. Stifel Fincl Corporation has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Ny State Teachers Retirement holds 0% or 41,790 shares in its portfolio. Spark Invest Ltd last reported 0.6% of its portfolio in the stock. Numeric Investors Ltd Liability Co, a Massachusetts-based fund reported 13,400 shares. Royal Bank Of Canada accumulated 0% or 18,245 shares. Proshare Advsrs Limited Liability Corporation holds 0% or 16,318 shares in its portfolio. Secor Capital Advsr Limited Partnership holds 0.12% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 42,938 shares.
More news for Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on March 25, 2013. Quotes.Wsj.com‘s article titled: “News Enanta Pharmaceuticals Inc.ENTA” and published on March 22, 2013 is yet another important article.
ENTA Company Profile
Enanta Pharmaceuticals Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Firm uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Firm is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.